precision-oncology-zhcn

Analyze precision oncology questions for specific cancer indications with structured decision support.

33|7|Updated Mar 19, 2026
One-click install
npx skills add https://github.com/patsnap/skills --skill precision-oncology-zhcn
Or copy as Structured Prompt for Agent
Please help me install this Agent Skill.
Skill: precision-oncology-zhcn
Source: https://github.com/patsnap/skills/tree/main/life-sciences/precision-oncology-zhcn
Command: npx skills add https://github.com/patsnap/skills --skill precision-oncology-zhcn

SYSTEM DOCUMENTATION & REQUIREMENTS

What problem does it solve?

This Skill helps users answer high-stakes precision oncology questions by connecting cancer biology, epidemiology, standard-of-care therapy, clinical development, and business relevance into one structured analysis.

Core Features & Use Cases

  • Tumor Mechanism Analysis: Explain cancer initiation, progression, signaling changes, and tissue-level pathology.
  • Epidemiology and Patient Segmentation: Summarize incidence, prevalence, subtype distribution, and regional or demographic differences.
  • Standard-of-Care Review: Compare first-line, second-line, and later-line treatments, diagnostics, efficacy metrics, and adverse events.
  • Pipeline and Opportunity Assessment: Identify emerging therapies, unmet needs, and commercial attractiveness for a given indication.
  • Use Case: A biotech team can use this Skill to assess whether a target or modality is compelling for a specific cancer type and how it should be positioned against current therapy.

Quick Start

Ask the skill to evaluate a specific cancer indication, including its biology, epidemiology, current treatment landscape, and emerging therapeutic opportunities.

Frequently Asked Questions about precision-oncology-zhcn

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I analyze precision oncology questions for a specific cancer indication?

To analyze precision oncology for a specific cancer indication, integrate literature, epidemiology reports, clinical guidelines, clinical trial data, and biomarker-focused evidence to produce structured decision support.

What is the best way to review standard-of-care treatments and identify unmet needs in oncology?

Reviewing standard-of-care oncology treatments requires comparing first-line, second-line, and later-line therapies, diagnostics, efficacy metrics, and adverse events to identify emerging therapies and commercial attractiveness for a given indication.

How do I assess cancer mechanisms and epidemiology for solid tumors and hematologic malignancies?

Assessing cancer mechanisms and epidemiology involves explaining cancer initiation, progression, signaling changes, and tissue-level pathology, while summarizing incidence, prevalence, subtype distribution, and regional or demographic differences.

Can I integrate clinical trial data and biomarker evidence to evaluate pipeline opportunities for a specific cancer type?

Yes, integrating clinical trial data and biomarker-focused evidence allows you to identify emerging therapies, unmet needs, and commercial attractiveness, helping biotech teams assess whether a target or modality is compelling for a specific cancer type.

Does precision oncology analysis work for both solid tumors and hematologic malignancies?

Precision oncology analysis applies to both solid tumors and hematologic malignancies, connecting cancer biology, epidemiology, standard-of-care therapy, clinical development, and business relevance into one structured analysis.